OSAKA, Japan - Thursday, 08. May 2025

Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024
Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings
Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated
FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation
Proposed Dividend Increase from JPY 196 to JPY 200
 

(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.

Takeda has built a high-value late-stage pipeline with pot ... Read more »

SINGAPORE - Friday, 09. May 2025 AETOSWire 

The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees

(BUSINESS WIRE)--Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities.

At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays.

Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Mod ... Read more »

Study conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus

(BUSINESS WIRE) -- VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials.

https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html

Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic ... Read more »